B7-H3 CAR-T Therapy for Pediatric DIPG/DMG
- sunshine4cancerkid
- 5 days ago
- 25 min read
Teju Merugu | Researcher / Writer
Grace Ryu | Researcher / Writer
Soumya Kundala | Researcher / Writer
Mariam Fadl | Researcher / Writer
Veera Patel | Researcher / Writer
Table of contents
Table of contents.......................................................................................................................2
Abstract.....................................................................................................................................3
Introduction..............................................................................................................................4
Research Question or Focus.................................................................................................... 4
Discussion................................................................................................................................. 5
Disease background and biology........................................................................................... 6
How to diagnose patients........................................................................................................8
Signs and Symptoms..................................................................................................................9
Typical age of diagnosis.............................................................................................................9
Medical Equipment, Physical Examinations, Imaging Tests, and etc............................ 9
1. Tissue Biopsy.....................................................................................................................9
2. Imaging tests.................................................................................................................. 10
3. Physical Exams............................................................................................................... 10
Staging or risk classification....................................................................................................10
Current Standard of Care...................................................................................................... 11
Current Standard Treatment....................................................................................................11
Clinical trial or research study................................................................................................. 13
Treatment results, risks, side effects, and limitations...................................................... 13
Treatments.............................................................................................................................. 14
Type of treatment...................................................................................................................... 14
How is it given to patients?......................................................................................................15
Which patients may qualify for it?..........................................................................................16
Statistics (DATA).....................................................................................................................17
Limitations...............................................................................................................................18
Eligibility restrictions................................................................................................................ 18
Long-term effects.......................................................................................................................18
Cost or accessibility concerns.................................................................................................18
Limited evidence or small study sizes................................................................................. 19
Questions that remain unanswered..................................................................................... 19
Impacts.................................................................................................................................... 19
Conclusion.............................................................................................................................. 20
Bibliography/Citations (MLA Format)..................................................................................21
Abstract
Diffuse Intrinsic Pontine Glioma (DIPG), a subtype of Diffuse Midline Glioma (DMG), is an
aggressive, universally fatal pediatric brainstem tumor most commonly diagnosed in children aged 5 to 9, with a median survival of just 9-12 months. Driven largely by the H3K27M histone mutation and located in inoperable regions of the brainstem, DIPG resists surgical removal, chemotherapy, and radiation, leaving families with no curative options. This paper examines B7-H3 (CD276) CAR-T cell therapy, an investigational immunotherapy that engineers a patient’s own T-cells to recognize and destroy tumor cells expressing B7-H3, a protein overexpressed on nearly all DIPG/DMG cells but minimally present in healthy brain tissue. Because the blood-brain barrier limits intravenous delivery, this therapy is administered directly into the cerebrospinal fluid via intracerebroventricular dosing. The leading study, Seattle Children's BrainChild-03 phase 1 trial (NCT04185038), demonstrated that repeated dosing was feasible and tolerable in 21 treated patients, with manageable side effects and a median survival modestly exceeding historical benchmarks, though responses varied and were not universal. This research explores how B7-H3 CAR-T works, what current clinical evidence shows about its safety and efficacy, and what limitations, including small trial sizes, unknown long-term effects, and restrictive eligibility criteria, still stand in the way of broader use. While B7-H3 CAR-T therapy remains experimental rather than a standard of care, it represents a meaningful shift toward targeted, immune-based treatment for a disease that has seen little therapeutic progress in
decades.
Introduction
Diffuse Intrinsic Pontine Glioma (DIPG), classified under Diffuse Midline Gliomas (DMG), is a fast-growing, aggressive pediatric brain tumor that develops in the pons region of the brainstem. Most of these tumors carry a specific genetic alteration called the H3 K27M mutation. This mutation interferes with normal histone protein functions, disrupting gene regulation, and causes the tumor to grow rapidly (Khuong-Quang et al.). Additionally, DIPG cells frequently overexpress an immune-checkpoint protein called B7-H3 on their surface, making it a strong target for therapeutic intervention. B7-H3 CAR-T Cell Therapy works by extracting a patient's own T-cells and genetically engineering them to express a Chimeric Antigen Receptor (CAR). This modification equips the immune cells to directly target and destroy cancer cells displaying the B7-H3 protein (Vitanza et al.).
Standard treatments struggle to treat DIPG due to several physical limitations. Surgery is impossible because the tumor grows directly inside the brainstem, which controls vital functions like breathing and heart rate. Chemotherapy also fails to work effectively because the blood-brain barrier stops most drugs from ever reaching the tumor (Warren). Currently, focal radiation is the primary option used to shrink the tumor and temporarily relieve symptoms, but it is not a permanent cure and nearly all DIPG cases return over time (Weisbrod et al.). Additionally, standard treatments can leave a developing child with severe long-term side effects
across their central nervous system. This is why targeted options like CAR-T cell therapy are necessary. They aim to destroy cancer cells specifically while leaving healthy brain tissue untouched (Vitanza et al.). CAR-T therapy has already shown major success with blood cancers like leukemia, so current research is focused on overcoming challenges like tumor delivery and local swelling to make it work safely for solid brain tumors in children (Epperly et al.).
B7-H3 CAR-T therapy is being developed for children and Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma ( DMG) primarily targets children and young adults aged 1-26 years, with highest concentration of patients between 5-10 years old. Researchers believe these tumors are linked to genetic changes that occur during brain development, making them much more common in children than adults.
Research Question:
How does B7-H3 CAR-T cell therapy work, and what makes it a promising treatment for
pediatric DIPG/DMG?
Discussion
Selecting Diffuse Intrinsic Pontine Glioma (DIPG) and B7-H3 CAR-T cell therapy as the focus of this research comes from the urgent need for better treatment options in pediatric oncology. Traditional cancer treatments like chemotherapy and radiation rarely succeed against DIPG because the tumor forms in a critical part of the brainstem (Hargrave). Instead of relying on these traditional methods, B7-H3 CAR-T therapy takes a different approach by engineering a patient’s own immune system to recognize and target the cancer cells directly. Studying this therapy helps determine how effective and safe these modified cells are for pediatric patients. This has opened new ideas for improved treatment strategies. Exploring this approach emphasizes how bioengineers can design T-cells capable of surviving the harsh tumor microenvironment, which often shuts down standard immune responses (Epperly et al.). Assessing the safety and efficacy of B7-H3 targeted therapies provides a valuable foundation that could be applied to other difficult-to-treat childhood brain and spinal cord cancers (Vitanza et al.).
Disease background and biology
Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG) are rare,
aggressive brain tumors that primarily affect children. Developing in the brain’s midline
structures, DIPG is commonly formed in the pons of the brainstem, while the DMG is formed in the midline of the brain, or spinal cord. These tumors grow in areas of the brain that control movement, breathing, heart rate, balance, and other essential functions. This means that the tumors can not be easily removed with surgery, risking interference with healthy brain tissue.
DIPG and DMG arise from glial cells, which are supportive cells that protect and nourish neurons in the central nervous system. The tumors infiltrate the healthy brain tissue by intertwining and spreading intricately, rather than forming into a localized mass. This causes these tumors to be very hard to be treated. The main areas affected include the Pons (brainstem), Thalamus, and Spinal Cord and Cranial Nerves (Nerves III, VI, VII, IX, X), which run directly through the brainstem and carry signals for face and eye movement. Since these tumors grow in
highly sensitive areas, they interrupt the transmission of signals to the rest of the body.
The H3K27M mutation, found in genes that encode histone H3 proteins (most commonly
H3F3A or HIST1H3B/C) are prevalent for pediatric DMGs. Histones are proteins that DNA wraps around to help regulate which genes are turned on or off. This mutation replaces the amino acid lysine (K) with methionine (M) at position 27 of histone H3. This disrupts the normal gene regulation that occurs throughout the cell. B7-H3 (CD276), a protein found in high amounts on the surface of many DIPG/DMG tumor cells, also plays a role. Though it’s not a mutation, it’s a tumor-associated antigen that can be recognized by engineered CAR-T cells, making it an
attractive target for immunotherapy.
B7-H3 (CD276) is a cell surface protein that is expressed at very low levels in normal brain
tissue but is overexpressed in almost all tumor cells associated with diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). This widespread overexpression is both the disease’s progression and its treatment. As a member of the B7 family of immune regulatory molecules, B7-H3 typically functions to suppress T cell activity. However, when tumor cells overexpress it, they send a “don’t attack me” signal that allows them to evade immune surveillance. This evasion adds to the challenges posed by underlying driver mutations, such as the commonly seen K27M mutation in histone H3, as well as by the tumor’s location in inoperable areas like the brainstem, pons, thalamus, or spinal cord. Interestingly, the same characteristic that helps the tumor avoid immune detection high levels of B7-H3 expression is found consistently on the tumor cells while exhibiting minimal expression in healthy brain tissue. This contrast makes B7-H3 a promising and relatively safe target for CAR-T therapy. Engineered T cells can be directed to seek out and destroy B7-H3 targeting CAR-T cells, found the treatment to be tolerable and indicated some clinical benefits in children with DIPG. However, not all patients responded, suggesting that tumor heterogeneity and the surrounding immune environment may limit the effectiveness of targeting this single protein.
Biological changes play a central role in the development and progression of DIPG/DMG. The disease is primarily driven by the H3K27M mutation, which disrupts normal epigenetic regulation of genes controlling cell growth and division, causing brainstem cells to proliferate uncontrollably and form aggressive tumors. Beyond this genetic driver, these tumors develop mechanisms to evade the immune system, notably by overexpressing the B7-H3 protein on their cell surface, which helps them avoid detection and destruction by immune cells. The tumor further reshapes its surrounding environment into an immunosuppressive microenvironment, making it more difficult to succeed. Together, these biological changes not only explain how the disease develops and survives but also point to promising therapeutic targets, such as B7-H3 CAR-T therapy, which is designed to selectively recognize and destroy B7-H3- expressing tumor
cells while minimizing harm to healthy brain tissue. DIPG/DMG is generally considered an acquired somatic condition. The H3K27M mutation occurs spontaneously in the tumor cells during a child’s development and is not passed down from parents or present in every cell of the body. There is currently no strong evidence that the
condition runs in families or is caused by inherited genetic mutations, and unlike some other pediatric brain tumors, it isn’t clearly linked to known genetic predisposition syndromes such as Li Fraumeni syndrome. The disease also tends to arise during a specific window of childhood brain development, suggesting that the mutation may interact with developmental biological vulnerability that is something inherited or caused by another disorder.
How to diagnose patients
Signs and Symptoms
Because Diffuse Intrinsic Pontine Glioma (DIPG) originates in the pons region of the
brainstem, it quickly compresses key pathways that control facial movement and body
balance. Symptoms usually develop rapidly over a short period of one to two months,
displaying as a diagnostic triad. The first part of this triad involves cranial nerve deficits,
which often cause double vision (diplopia), dropping on one side of the face, or difficulty
swallowing and speaking (dysphagia and dysarthria). Patients also experience ataxia,
leading to balance issues, a loss of motor coordination, general clumsiness, and weaknessin the limbs. As fluid builds up or the tumor creates mass effect within the brainstem, patients show signs of increased intracranial pressure, which commonly shows recurrent morning headaches, nausea, and vomiting (Johung and Monje).
Typical age of diagnosis
DIPG is primarily a pediatric malignancy, with the immense majority of cases occurring
in young children. The disease is most commonly diagnosed in children between 5 and 9
years old, with the peak incidence occurring around ages 6 to 7. While DIPG can
occasionally show in infants or older adolescents, it remains almost exclusively a disease
of early childhood (Karsonovich and Hall).
Medical Equipment, Physical Examinations, Imaging Tests, and etc
Many medical equipment and examinations are involved in diagnosing DIPG and determining eligibility for CAR-T therapy. These include:
1. Tissue Biopsy
- DIPG is diagnosed mainly by MRI, but a biopsy is increasingly done at diagnosis for
molecular/target conformation, since brainstem surgery for full resection is not feasible.
- Microtome: Used post biopsy to cut the fixed, paraffin-embedded tumor issues into thin sections (typically 4-5 um) mounted on slides. This is the mechanical prerequisite for all downstream histologic and immunohistochemical work
- IHC (immunohistochemical): IHC can serve as an important eligibility assessment by
conforming B7-H3 expression in tumor tissue when tissue samples are available or required by protocol. This determines trial eligibility. Across B7-H3 CAR-T protocols, tumor tissue must show positive B&3 expression in tumor tissues as confirmed by immunohistochemistry. Some trials for other CNS/ solid tumors add a quantitative threshold -e.g., > 30% dating extent of B7-H3 by the immunochemical method- thought B7-H3- specific DIPG trails have generally not needed as strict cutoff, since B70H3 is expressed on DIPG essentially universally, based on prior work establishing it as a target. If archival tissue exists (e.g., from an earlier biopsy at diagnosis or autopsy), some protocols allow use of previously obtained samples rather than requiring a fresh biopsy.
2. Imaging tests
MRI: Primary diagnostic and eligibility modality. DIPG diagnosis is fundamentally radiographic.The canonical criteria: a tumor with a pontiine epicenter and diffuse involvement of teh majority of the brainstem on T2 or FLAIR imaging rather than focal, with some protocols specify diffuse involvement of more than 2⁄3 of the pons and without evidence of dissemination. Critically, most trials explicitly state histologic conformation is not required when radiographic criteria are met-meaning MRI alone can satisfy diagnostic eligibility, biopsy/IHC becomes necessary only whenimaging is atypical or when B7-H3 status specifically needs conformation.
CT (computerized tomography): B7-H3 CAR-T delivery is via an indwelling catheter into the tumor resection cavity or into their ventricular system, CT is used for surgical.catheter placement planning rather than initial diagnosis. IT also factors into exclusion screening for clinical or radiographic evidence of impending hernaition.
PET (possession emission tomography): In adult recurrent glioblastoma B7-H3 CAR-T trials, relapse can be confirmed by PET or histologic pathology. This is less central in de novo DIPG (where the MRI dominates) but many support assessment of refractory pediatric CNS tumors in broader eligibility categories.
3. Physical Exams
Neurological Examination: Supports the initial diagnostic assessment, as the brainstem location of DIPG frequently produces carinal nerves, palsies, ataxia, and other long tract neurological signs, and it generated the functional performance status score used as formal eligibility criterion. Most trials employ either the Lansky or Karnofsky performance status scales, with minimum required scores varying by protocol: some studies require a score of at least 50, while others, including the BCB-276 pivotal trial, require a threshold of 60 or higher.
Cardiac and Pulmonary Examination: Used to confirm adequate organ function, a standard inclusion requirement across CAR-T protocols, while simultaneously screening for disqualification conditions such as grade 3 or higher cardiac dysfunction or symptomatic arrhythmias requiring clinical intervention. Also, verifies that a patient can safely trial the leukapheresis procedure required to collect T-cells for CAR- manufacturing, as well as the anesthesia associated with catheter placement for locoregional drug delivery. Pulmonary assessment requires a minimum room air oxygen saturation of 90% for eligibility.
Staging or risk classification
Diffuse intrinsic pontine glioma ( DIPG ) and diffuse midline glioma ( DMG ) are considered high risk brain tumors because of how aggressively they grow, where they’re located, and how few treatment options exist for them. DIPG/DMG is considered a high risk due to its location.These tumors sit in the brainstem, specifically the pons, which controls essential functions: breathing, swallowing, etc...Because of the where the tumor is presented the doctors generally can’t surgically remove it, catalyzing aggressive risks such as neurological damage. Without the option to surgically remove the tumor, it’s much more likely to keep growing and progressing. Many DIPG/DMG tumors carry alterations in the H3K27 gene pathway most notably the H3K27M mutation, which is linked to more aggressive tumor behavior and worse outcomes. These molecular changes drive abnormal tumor growth and make the disease more resistant to standard treatments, which makes it harder to manage overall.
Current Standard of Care
Current Standard Treatment.
There is not a standard of care for B7-H3 CAR-T itself yet. It is investigational, not an approved treatment protocol, but the most advanced protocol comes from the BrainChild-03 phase 1 trial (NCT04185038) at Seattle Children’s. It uses repeated intracerebroventricular (CV) dosing. Meaning, the CAR-T cells are infused directly into the cerebrospinal fluid via a ventricular catheter/reservoir, rather than given intravenously as with blood cancer CAR-T therapies. Dosing follows an intra-patient dose escalation approach, with no lymphodepletion given beforehand (unlike most CAR-T protocols for leukemia/lymphoma), and treatment is repeated over time. Some patients received doses for multiple years. The trial reached a highest planned dose of 100 million CAR-T cells, which was found tolerable. This ICV, repeat dosing, no lymphodepletion regimen is currently the closest thing to an established protocol for B7-H3 CAR-T in DIPG/DMG, and it’s now being carried forward into planned multi-site phase 2 trials, sometimes in combination with other agents like ONC206, rather than being used as a finalized standard treatment.
B7-H3 CAR-T therapy is an investigational treatment for diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG), fatal pediatric brainstem tumors that are inoperable due to their location, resistant to chemotherapy, and only temporarily responsive to radiotherapy, with the current standard of care leaving median survival at
just 9-12 months. The therapy exploits B7-H3 (CD276), a protein overexpressed on
nearly all DIPG/DMG tumor cells but minimally present on healthy brain tissue, by
engineering a patient’s T cells to express a chimeric antigen receptor (CAR) that binds
B7-H3 directly and triggers the T cells to proliferate and destroy tumor cells through
cytotoxic granule release and cytokine signaling. Because the blood-brain barrier limits
how well intravenously delivered cells reach the brainstem, these CAR-T cells are instead
delivered intracerebroventricularly (directly into the cerebrospinal fluid) with repeated
dosing over time rather than a single infusion. The leading trial, BrainChild-03 (Seattle
Children’s NCT04185038), has demonstrated that this approach is feasible and tolerable,
including with multi-year repeated dosing, and some patients have survived well beyond
the typical median; however, since responses have not been uniform across all patients,
the therapy remains investigational rather than an established standard of care, with
research how advancing toward larger phase 2 trials and combination strategies to
improve consistency of benefit.
It’s experimental but not FDA-approved. B7-H3 CAR-T for pediatric DIPG/DMG still is
confined to early phase clinical trials, most known is the Seattle Children’s/Fred Hutch
Brain Child-03 trail where a phase 1, single center, dose-escalation study that give
repeated intracerebroventricular B7-H3 CAR-T infusions to kids with recurrent and
refractory CNS tumors and DIPG. Results published in Nature Medicine delivered 253
total doses with headache, fatigue and fever as the most common side effects and just one dose limiting toxicity. Median survival from CAR-T infusion was 10.7 months post
diagnosis which is better than the 11 month median survival that's typical for untreated
DIPG but the response wasn’t universal across all the patients because of that researches now looking into combo strategies such as pairing B7-H3 CAR-T with the drug ONC26 and other trials like St.Jude Loc3CAR is testing similar approaches too. As this is promising early data, this therapy is still years away from FDA approval and right now it's only accessible if you enroll in a clinical trial not as a standard of care treatment yet.
Clinical trial or research study.
BrainChild-03 trial (NCT04185038) which was run by Dr. Nicholas Vitanza at Seattle
Children's and was published in Nature Medicine in 2025. This phase 1 trial tested B7-H3
CAR T cells which is a type of immunotherapy that target a protein called B7-H3 that's
found on almost all DIPG enrolled and 21 was treated with repeated doses of the CAR T
cells delivered directly into the brain's ventricles, the researchers ended up delivering 253 total doses with the highest tolerated dose regimen escalating up to 10 x 10^7 cells per dose. The main goal of the trial which was to see if the treatment was feasible and
tolerable was both met though there was one serious side effect which was a bleed in the
tumor and more common side effects like headache, fatigue and fever. For the patients
who got treated, median survival from diagnosis is significant because DIPG usually only
gives kids about 9-11 months to live untreated. This trial shows that B7-H3 CAR T
therapy is safe enough to keep studying and could actually help some kids live way
longer than expected.
Treatment results, risks, side effects, and limitations.
In terms of treatment results the trial showed that repeated dosing was possible over a
long period of time with some patients getting treatment for years and while it didn't
work the same for everybody, a few patients had really long survival compared to what's
typical for DIPG. As far as risks and side effects go, the most common ones were
headache, fatigue and fever and there was one dose limiting toxicity which was a bleed
inside the tumor that happened during dose regime 2 which shows that the side effect
profile seems pretty manageable compared to a lot of other cancer treatments. There's
some real limitations to this study as well as it was only a phase 1 trail done at one single
center, so the sample size was small where only 21 patients actually got treated and there wasn’t no control group to compare against which made it hard to know for sure how much of the survival benefit is really because of the CAR T cells vs other factors. Also, the response to therapy wasn’t universal meaning not every kid benefited and researchers still don't fully understand why some patients did way better than others because of these limitations the researchers said the results warrants further investigation in a bigger, multisite phase 2 trial before anybody can say for sure how effective this treatment really is.
Treatments
Type of treatment
The treatment analyzed in this research is B7-H3 CAR-T Cell Therapy (specifically
targeted chimeric antigen receptor T-cell therapy), a form of targeted cellular
immunotherapy. Unlike traditional cancer treatments that rely on standard systemic drugs or radiation to eliminate cancer cells, CAR-T cell therapy extracts the patient’s own
immune system. The process involves taking T-cells (a type of white blood cell) from the
patient’s blood and genetically engineering them in a laboratory. Once modified, these
T-cells express a synthetic receptor that allows them to specifically recognize, track
down, and destroy brain tumor cells (Vitanza et al.).
This therapy specifically targets the B7-H3 protein (also known as CD276), an
immune-checkpoint protein that is expressed on the surface of DIPG and Diffuse Midline
Glioma (DMG) cells (Zhou et al.). While it doesn’t directly target the H3 K27M genetic
mutation responsible for tumor initiation, it takes advantage of the fact that DIPG cells
overproduce B7-H3 compared to normal, healthy brain tissue. This additionally gives the
engineered T-cells a clear target to lock onto and, minimizing off-target damage to
non-cancerous brain structures (Maachani et al.).
How is it given to patients?
B7-H3 CAR T is still investigational (given only within clinical trials, not an approved standard of care therapy), and the delivery method depends heavily on the tumor type and trial. Here’s how it's actually being administered across current trails
1. Intravenous ( IV ) infusion - Systemic IV infusion is the most common delivery route for B7-H3 CAR-T therapy in extracranial solid tumors, such as pancreatic cancer. In this approach, the patient's own T cells are collected, engineered to express the anti-B7-H3 receptor, expanded in the lab, and then infused back into the patients via IV, typically over 5-10 minutes. Most systemic B7-H3 CAR-T trials use this route, and it usually
proceeds by lymphodepleting chemotherapy, which clears out existing lymphocytes to make room for the engineered cells to explain and persist.
2. Intracerebroventricular ( ICV) - Brain tumors ( ex. DIPG). For diffuse intrinsic pontine glioma (a brainstem tumor), cells are delivered directly into the cerebrospinal fluid via a reservoir/catheter system rather than IV> In the St. Jude BrainChild-03trailm researchers conducted repetitive intracerebroventricular dosing B7-H3 CAR T cells for children with recurrent or refractory CNS tumors and DIPG.
3. Intraperitoneal (IP) - Cancers confined to the abdominal cavity. In an ovarian cancer trail, iC9-CAR.B7-H3 T cells are administered intraperitoneally, following IV cyclophosphamide and fludarabine as lymphodepletion - delivering the cells directly into the abdominal cavity where the tumor is located.
Which patients may qualify for it?
Patients who may qualify for B7-H3 CAR T treatments are almost children, adolescents, or young adults with a relapsed B7-H3 positive solid tumor that has progressed despite standard first-line therapy, since these trails generally enroll patients up to 21 years old ( with a least one adult-focused trial for pancreatic cancer requiring patients to be 18 or older). Candidates must have measurable disease and , in most trials, confirmed B7-H3 expression on a tumor biopsy. They also need sufficiently healthy organ function to tolerate treatment, including adequate heart function( ejection fraction above 40%), kidney function, liver enzymes and bilirubin within set limits and enough bone marrow reserve. Patients are excluded if they have a primary immunodeficiency, a history of HIV infection, an active or severe uncontrolled infection, rapidly progressing disease, a history of allergic reaction or if they’re on high dose steroids or other therapies that could not interfere with the CAR T cells activity shortly before the infusion. Additional particle requirements include being eligible for apheresis ( procedure used to collect T cells), avoiding pregnancy or breastfeeding during the treatment, and committing to long term followup. These are experimental gene-modified cell therapies delivered exclusively through trials rather than a standard treatment.
B7-H3 CAR T cell therapy is entirely investigational. No version of it has FDA approval and none is close to a standard care recommendation. Every program currently sits in early phases clinical trials, almost all Phase 1, spanning a range of cancer including pediatric batin tumors ( DIPG) glioblastoma, ovarian cancer and various relapsed or refractory pediatric solid tumors. The most advanced candidate is BCB-276, which targets DIPG and has picked up two special FSA designations along the way: breakthrough therapy and regenerative medicine advancement therapy (RMAT). Both of these exist specifically to expedite development and regulatory conversion for priming early therapies, but neither one is an approval or guarantees the treatment would reach the market. Other trials, such as the glioblastoma study at UNC(LCCC 2059) and the allogenic “ off the shelf” approach called UTAA06,are still stuck in dose escalation. B7-H3 CAR T is real, and it’s active and it’s producing early results, but it’s still firmly in the “ currently studied” category rather than anything patients can assess an approved treatment outside of a clinical trial.
It's a totally different kind of treatment, not just a tweak to what’s already out there. Radiation and chemo, which is what most of these cancers get treated with, basically hit healthy and cancerous cells at the same time without much precision. CAR T works the opposite way . It takes a patient's own T cells and rewrites them, to specifically go after cells with the B7- H3 protein on them. The whole process looks different too. Cells have to be collected and engineered in a lab first, patients usually need chemo beforehand just to clear space for the new cells, and depending on where the tumor is, doctors might deliver it straight into the brainA or abdomen instead of through a regular IV. For DIPG specifically, there’s not really a solid standard of care to compare it to in the first place. Radiation buys some time but doesn't change the long term outcome much, which is exactly why CAR T is getting so much attention there and also why nobody's ready to call it an actual treatment yet. A few things make that hard to do. B7-H3 shows up on some healthy cells too, not just tumor cells, so there's a real risk of threat affecting more than it should. Solid tumors are also just harder targets than blood cancers since they've got physical barriers around them and don't express the target protein evenly. Most of what's known so far comes from small trials, often under 25 patients with no control group, so the results are promising but not proof. The threat is also being tested across a bunch of different cancers with different delivery methods, so success in one does not guarantee success in another. And since follow up has only gone on for a couple of years, nobody knows yet if the responses
will actually last.
Diffuse Intrinsic Pontine Glioma (DIPG) is a rare pediatric brain cancer, with approximately 200 to 300 new cases diagnosed annually in the United States. Although DIPG represents only 10% to 20% of all pediatric central nervous system tumors, it accounts for nearly half of all high-grade gliomas in children. The disease occurs almost exclusively in pediatric age groups, with most diagnoses occurring in children between 5 and 9 years of age and peaking specifically around 6 to 7 years old.
Prognosis for DIPG remains exceptionally severe compared to other pediatric malignancies. The overall survival rate following standard radiation diagnosis is typically 8 to 11 months, with fewer than 10% of patients surviving past two years and less than 1% reaching five-year survival. Because traditional chemotherapies fail to improve survival outcomes, clinical research has focused on novel cellular immunotherapies. Early clinical trials investigating B7-H3 CAR-T cell therapy such as the BrainChild-03 phase 1 trial, demonstrated that repeatedly infusing modified T-cells directly into the brain’s ventricular system was well-tolerated in pediatric patients, showing promising signs of local immune activation and extending overall survival in several trial participants.
Limitations
Eligibility restrictions
B7-H3 CAR-T cell therapy is currently only available through clinical trials and limited to patients that meet the specific eligibility requirements. Patients must have tumors that express the B7-H3 protein, sufficient heart, liver, kidney, and bone marrow function. They must also be healthy enough to undergo leukapheresis, which is the process to collect T-cells. Many trials also do not include patients with severe infections, significant immune disorders, or other rapidly progressing disease. As a result, not every child is able to receive this therapy.
Long-term effects
Because CAR T cell therapy involves permanent genetic modification of autologous or allogenic T cells, the durability and safety of this modification over extended time horizons remains largely uncharacterized. Follow up periods across published and ongoing trails rarely extended beyond several years, and the longest reported outcomes, such as those from the completed DIPG trail(NCT0418538), still represent a relatively narrow observation window. Consequently, data are insufficient to assess potential late onset toxicities, long term immune competence, secondary malignancy risk associated with genetic modification or the cumulative effects of
repeated dosing regiments, which are used in several intracerebroventricular protocols. This concern is particularly salient in pediatric populations, where treatment occurs during active physiological development and any latent effects would have a proportionally longer period to manifest.
Cost or accessibility concerns
CAR T cell products are inherently resource intensive, as each dose typically requires individualized cell collection, ex vivo genetic engineering and expansion prior to reinfusion, a process that is both technically complex and costly relative to conventional chemotherapeutic agents. Even in the event of eventual regulatory approval, the manufacturing infrastructure required is likely to remain concentrated at specialized academic medical centers constraining geographic and economic accessibility.
Limited evidence or small study sizes
The existing evidence base for B7-H3 CA T cell therapy is derived almost entirely from early phase, single arm, dose escalation studies enrolling small cohorts, often between ten and twenty five patients, without randomized comparatory groups. This study design, while appropriate for establishing preliminary safety and tolerability, limits the ability to draw statistically robust conclusions regarding efficacy relative to existing treatment approaches or natural disease progression. Reported outcomes, including survival benefits observed in DIPG cohorts, should therefore be interpreted as hypothesis generating archer than confirmatory, pending validation in larger, adequately powered and ideally randomized trials.
Questions that remain unanswered
Several questions still remain unanswered about B7-H3 CAR-T therapy. Researchers are still investigating as to why some patients respond better than others, how their tumors become specifically resistant to this treatment, and how to overcome the immunosuppressive tumor microenvironment that can reduce CAR-T cell activity. Scientists are still studying whether combining B7-H3 CAR-T therapy with other treatments, such as targeted drugs or radiation therapy, can be proven to be more effective. As research continues, B7-H3 CAR-T therapy will remain an experimental approach rather than a standard of care until larger clinical trials can be held.
Impact of DIPG/DMG on Children and Youth
Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG) have devastating effects on children and adolescents because they develop in the brainstem, the area responsible for essential bodily functions. As the tumor grows, children often experience progressive symptoms such as difficulty in walking, loss in balance, weakened vision, facial weakness, slurred speech, and problems with swallowing. Over time, these symptoms may worsen, leading to an increased dependence on caregivers.
This disease also has significant emotional and psychological impacts. Children with DIPG and DMG often face anxiety, fear, and uncertainty, as they undergo numerous hospital visits, radiation therapy, and experimental clinical trials. At the same time, parents and siblings experience emotional stress while dealing with their child’s prognosis. DIPG and DMG also disrupt normal childhood development. Many patients will miss school because of medical appointments, hospitalizations, or worsening neurological symptoms, making it difficult to keep up with friends and academics. This reduced participation in social activities can contribute to feelings of isolation and depression, especially during a critical stage in childhood development. Despite current medical treatments and advancements, the survival rate for children with DIPG remains less than one year (median of nine to twelve months). This places an increased burden on hospital providers and caregivers due to the limited time period.
Conclusion
B7-H3 (CD276) has emerged as one of the promising targets for CAR-T cell threat in solid tumors, particularly in aggressive pediatric cancers such as diffuse intrinsic pontine glioma (DIPG), neuroblastoma, osteosarcoma and Ewing sarcoma, where treatment options remain limited and outcomes are often poor. Because B7-H3 is highly expressed across many solid tumor types while shared with healthy cells, early phase trials have already shown the approach to be feasible and generally safe, with some patients experiencing durable tumor regression. Raising awareness of this work matters most among the groups positioned to act on it: pediatric oncologists,families facing relapses of refractory disease and patient advocacy organizations who can benefit from clearer information about ongoing trials through hospital cancer centers, disease specific foundations and accessible science communication that helps eligible patients find studies they might otherwise never hear about. At the same time real questions remain unanswered. Expansion, persistence and overall therapeutic efficacy of B7-H3 targeted CAR-T cells remain suboptimal in most patients,researchers still don’t fully understand why a minority of patients respond durably while most do not and there is ongoing work to move away from CAR designs built on mouse derived antibodies since non-human sequences can provoke immune responses that lead to CAR T cell rejection and treatment failure. The obstacles ahead are as much biological as logistical. CAR-T cells must localize to and penetrate solid tumor sites, survive a hostile tumor microenvironment, sustain meaningful expansion and persistence and overcome intrinsic tumor resistance. More broadly across solid tumor CAR-T research, antigen heterogeneity driven escape, and immunosuppressive microenvironment, limited in vivo persistence and treatment related toxicity continued to constrain efficacy and slow clinical adoption on top of practical burden of costly manufacturing and the intensive lymphodepletion chemotherapy most protocols still require. Taken together, B7-H3 CAR-T therapy represents genuine progress rather than a finished answer and the path forward will depend on continued data trials, smarter CAR engineered and sustained investment in research areas that disproportionately affect children with few other options left to try.
Bibliography/Citations (MLA Format)
“A Phase I Study of Autologous CAR-T Cells Targeting the B7-H3 Antigen and
Containing the Inducible Caspase 9 Safety Switch in Subjects With Refractory Pancreatic
Ductal Adenocarcinoma (PDAC).” ClinicalTrials.gov, Identifier NCT06158139, U.S.
National Library of Medicine, https://clinicaltrials.gov/study/NCT06158139. Accessed 25
July 2026.
“Administration of T Cells Expressing B7-H3 Specific Chimeric Antigen Receptors
(CAR) and Containing the Inducible Caspase 9 Safety Switch in Subjects.”
ClinicalTrials.gov, Identifier NCT06305299, U.S. National Library of Medicine,
https://clinicaltrials.gov/study/NCT06305299. Accessed 25 July 2026.
“3CAR: B7-H3-Specific CAR T-Cell Therapy for Children and Young Adults with
Solid Tumors.” St. Jude Children's Research Hospital,
25 July 2026.
“Epigenetic and Metabolic Changes in Diffuse Intrinsic Pontine Glioma.” Brain
Tumor Research and Treatment, vol. 11, no. 2, 1 Apr. 2023,
Epperly, Rebecca, et al. “CAR T Cells Redirected to B7-H3 for Pediatric Solid
Tumors: Current Status and Future Perspectives.” EJC Paediatric Oncology, vol. 3,
2024, p. 100160, https://doi.org/10.1016/j.ejcped.2024.100160.
22
“Engineering Functionality-Optimized Fully Human B7-H3 CAR T Cells for
Enhanced Solid Tumor Therapy.” Cell Reports Medicine, 2026,
https://doi.org/10.1016/j.xcrm.2026.102782. Accessed 27 July 2026.
Guo, J., et al. “Challenges and Breakthroughs: Current Landscape and Future
Prospects of CAR-T Cell Therapy Clinical Trials for Solid Tumors.” Frontiers in
Oncology, 2025, https://doi.org/10.3389/fonc.2025.1652329. Accessed 27 July
2026.
Hargrave, Darren. “Pediatric Diffuse Intrinsic Pontine Glioma: Can Optimism
Replace Pessimism?” CNS Oncology, vol. 1, no. 2, Nov. 2012, pp. 137–48,
https://doi.org/10.2217/cns.12.15. Accessed 24 July 2026.
Jansen, Lena, et al. “B7-H3 in the Tumor Microenvironment: Implications for CAR
T Cell Therapy in Pediatric Solid Tumors.” Cancer and Metastasis Reviews, vol. 44,
no. 4, Oct. 2025, https://doi.org/10.1007/s10555-025-10294-y.
Johung, Tessa, and Michelle Monje. “Diffuse Intrinsic Pontine Glioma: New
Pathophysiological Insights and Emerging Therapeutic Targets.” Current
Neuropharmacology, vol. 15, no. 1, Dec. 2016, pp. 88–97,
https://doi.org/10.2174/1570159x14666160509123229. Accessed 25 July 2026.
Karsonovich, Torin, and Walter A. Hall. “Diffuse Intrinsic Pontine Glioma.”
StatPearls, StatPearls Publishing, 2025,
https://pubmed.ncbi.nlm.nih.gov/32809475/. Accessed 25 July 2026.
23
Khuong-Quang, Dong-Anh, et al. “K27M Mutation in Histone H3.3 Defines
Clinically and Biologically Distinct Subgroups of Pediatric Diffuse Intrinsic Pontine
Gliomas.” Acta Neuropathologica, vol. 124, no. 3, June 2012, pp. 439–47,
Maachani, Uday B., et al. “B7-H3 as a Prognostic Biomarker and Therapeutic Target
in Pediatric Central Nervous System Tumors.” Translational Oncology, vol. 13, no.
2, Feb. 2020, pp. 365–71, https://doi.org/10.1016/j.tranon.2019.11.006. Accessed 25
July 2026.
National Cancer Institute. “T-Cell Transfer Therapy - Immunotherapy.” National
Cancer Institute, 1 Apr. 2022,
therapy. Accessed 28 July 2026.
“Phase 1 Clinical Trial Identifier NCT04897321.” ClinicalTrials.gov, U.S. National
Library of Medicine, https://clinicaltrials.gov/study/NCT04897321. Accessed 25
July 2026.
Vitanza, Nicholas A., et al. “Intracerebroventricular B7-H3 Targeting CAR T Cells
for Diffuse Intrinsic Pontine Glioma: A Phase 1 Trial.” Nature Medicine, vol. 31, 7
Jan. 2025, pp. 861–68, https://www.nature.com/articles/s41591-024-03451-3.
Accessed 25 July 2026.
Vitanza, Nicholas A., et al. “Intraventricular B7-H3 CAR T Cells for Diffuse
Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.”
24
Cancer Discovery, Oct. 2022, pp. OF1–18,
https://doi.org/10.1158/2159-8290.cd-22-0750. Accessed 23 July 2026.
Warren, Katherine E. “Diffuse Intrinsic Pontine Glioma: Poised for Progress.”
Frontiers in Oncology, vol. 2, 2012, https://doi.org/10.3389/fonc.2012.00205.
Accessed 23 July 2026.
Weisbrod, Luke J., et al. “Diffuse Intrinsic Pontine Glioma (DIPG): A Review of
Current and Emerging Treatment Strategies.” Cancer Letters, vol. 590, May 2024, p.
216876, https://doi.org/10.1016/j.canlet.2024.216876.
“What is the Difference between DIPG and DMG and What is the H3K27M Histone
Mutation?” The Cure Starts Now, 17 June 2020,
-what-is-the-h3k27m-histone-mutation/.
Zhou, Zhiping, et al. “B7-H3, a Potential Therapeutic Target, Is Expressed in
Diffuse Intrinsic Pontine Glioma.” Journal of Neuro-Oncology, vol. 111, no. 3, Feb.
2013, pp. 257–64, https://doi.org/10.1007/s11060-012-1021-2. Accessed 25 July
2026.
Comments